Diabetes microangiopathy gene susceptibility detection kit and group of SNP (Single Nucleotide Polymorphism) sites applied by kit

A microvascular lesion detection kit technology, which is applied in the direction of recombinant DNA technology, microbial measurement/testing, DNA/RNA fragments, etc., to achieve the effect of evaluating the risk of disease and predicting the genetic susceptibility of subjects to microvascular lesions

Pending Publication Date: 2022-03-01
石家庄市第二医院 +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, many genetic susceptibility genes of DR or DN have been found in the world, such as vascular endothelial growth factor (VEGF), advanced glycation end product (RAGE) receptor gene, interleukin-related gene, vitamin D receptor gene, Methylenetetrahydrofolate reductase gene (MTHFR), etc., but there are no products and methods for detecting genes related to diabetic microangiopathy in Chinese Han population

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Diabetes microangiopathy gene susceptibility detection kit and group of SNP (Single Nucleotide Polymorphism) sites applied by kit
  • Diabetes microangiopathy gene susceptibility detection kit and group of SNP (Single Nucleotide Polymorphism) sites applied by kit
  • Diabetes microangiopathy gene susceptibility detection kit and group of SNP (Single Nucleotide Polymorphism) sites applied by kit

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0033]This embodiment relates to the design of multiple PCR primer sequence sets and the detection application of the kit for the detection of gene susceptibility to diabetic microangiopathy.

[0034] 1. Primer design

[0035] According to the primer design requirements of SNaPshot typing technology, design specific amplification primers and single-base extension primers for 22 SNP sites. The sequences of the amplification primers and single-base extension primers are shown in the table below:

[0036]

[0037]

[0038]

[0039] 2. Genomic DNA extraction from peripheral blood

[0040] The peripheral blood of the subject was extracted, and the blood genomic DNA extraction kit (Tiangen Biochemical Technology Co., Ltd., DP348) was used to extract the subject's genomic DNA according to the procedure of the kit instruction manual.

[0041] 3. Multiplex PCR reaction

[0042] (1) Prepare the amplification primer mixture according to the following grouping, so that the fina...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a diabetic microangiopathy gene susceptibility detection kit and a group of SNP (Single Nucleotide Polymorphism) loci applied by the kit, the group of SNP loci comprises 11 SNP loci related to diabetic retinopathy and 12 SNP loci related to diabetic nephropathy, and the invention also discloses amplification primer sequences and single-base extension primer sequences corresponding to 22 SNP loci. A diabetic microangiopathy gene susceptibility detection kit composed of the amplification primer sequence and a single-base extension primer sequence is used for rapidly, effectively and accurately predicting the genetic susceptibility of microangiopathy of a subject and evaluating the onset risk of microvascular complications of diabetic patients. And follow-up visit and early intervention and early guidance of high-risk patients are facilitated.

Description

technical field [0001] The invention relates to the technical field of a diabetic microangiopathy gene detection kit, in particular to a diabetic microangiopathy gene susceptibility detection kit and a group of SNP sites used therefor. Background technique [0002] Type 2 diabetes, also known as non-insulin-dependent diabetes, is characterized by the fact that the human body can produce insulin itself, but due to insulin resistance, cells cannot respond to it, which greatly reduces the effect of insulin, that is, a condition caused by relative insufficient insulin secretion. It is a clinically common endocrine and metabolic disease that can occur at any age. With the development of society and economy, changes in people's lifestyles (increased energy intake and reduced exercise, etc.) and population aging, the incidence of type 2 diabetes is increasing year by year globally, according to data released by the International Diabetes Federation in 2017. There are about 114 mill...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883C12Q1/6858C12N15/11
CPCC12Q1/6883C12Q1/6858C12Q2600/156C12Q2600/16C12Q2600/166C12Q2531/113C12Q2537/143C12Q2545/113C12Q2565/125
Inventor 刘赞朝杜蒙赵增毅李洋胡庆山
Owner 石家庄市第二医院
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap